Is MS therapy getting to be too much for general neurologists?
July 22, 2013|Clinical Neurology News
Author and Disclosure Information
EXPERT ANALYSIS FROM THE CMSC/ACTRIMS ANNUAL MEETING
She added that she views the development of shingles in a patient on fingolimod as a potential red flag warranting serious consideration of a switch to another agent.
Dr. Kita reported receiving research support from Biogen Idec, Novartis (which markets Gilenya), Serono, and Acorda, and personal compensation from Biogen Idec, Bayer, and Genzyme.
